Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Mylan's Generic Version Of Tricor Tablets For Cholesterol Gets FDA Approval

RELATED NEWS
Trade MYL now with 

Generic drug maker Mylan Inc. (MYL: Quote), Friday said its unit Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application or ANDA for the generic version of Abbvie Inc.'s (ABBV: Quote) cholesterol drug Tricor or Fenofibrate.

Mylan said that its unit Mylan Pharmaceuticals Inc. has shipped Fenofibrate Tablets, 48 mg and 145 mg. The drug is prescribed as an adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol, total cholesterol, Triglycerides and apolipoprotein B, and to increase high-density lipoprotein cholesterol in adult patients. Fenofibrate Tablets also are indicated for treatment of adult patients with severe hypertriglyceridemia or high blood levels of triglycerides.

Click here to receive FREE breaking news email alerts for Mylan Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Computer and printer maker Hewlett-Packard Co. said Tuesday after the markets closed that its fourth quarter profit fell 6% from last year, as revenue declined 2%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. This organic and natural products company has experienced strong compounded annual growth over the last four fiscal years with its net sales growing 25% and adjusted income from continuing operations over 30%. Here is a quick summary of the earnings reported after the bell on Nov. 24. 1. Amira Nature Foods Ltd (ANFI) reported net income for the second quarter of $8.3 million or $0.29 per share, compared to $5.0 million or $0.18 per share for the year-ago quarter. Excluding items, adjusted earnings...
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.